Predictive factors for differentiating thrombohemorrhagic disorders in high-risk acute promyelocytic leukemia
Mengyu Xiao,Pan Zhou,Yanhui Liu,Shengjie Wei,Dan Li,Weiya Li,Xiaona Niu,Junwei Niu,Yinyin Zhang,Weijie Cao,Bing Liu,Xiaojiao Wang,Yanliang Bai,Kai Sun
DOI: https://doi.org/10.1016/j.thromres.2021.12.020
IF: 10.407
2022-02-01
Thrombosis Research
Abstract:INTRODUCTION: Acute promyelocytic leukemia (APL) is often accompanied by potentially fatal coagulopathy, especially in high-risk APL. Bleeding, particularly severe bleeding is the leading cause of early death (ED). Meanwhile, thrombosis, the other major coagulopathic complication, is being increasingly recognized. However, predictors of thrombohemorrhagic disorders are still not well investigated.MATERIALS AND METHODS: In this study, we retrospectively studied 83 patients with high-risk APL and categorized them into severe bleeding, thrombosis and no evident events groups.RESULTS: Severe bleeding was observed in 15 patients, nearly half of whom died of hemorrhage, while thrombosis was observed in 12 patients. Risk factor analysis showed that high WBC (>58.76 × 10<sup>9</sup>/L) (p = 0.001) and prolonged PT (>17.7 s) (p = 0.015) could be independent predictors for severe bleeding, while high WBC/D-dimer>5.12 (p = 0.002) and low D-dimer/FIB<5.14 (p = 0.03) could be independent predictors for thrombosis in high-risk APL patients. Moreover, there are significant differences in WBC/D-dimer and D-dimer/FIB between DIC and Non-DIC groups (p < 0.001). Notably, we found that the WBC/D-dimer was dramatically higher in the thrombotic group than in the other two groups at the time of admission or during the first week of induction therapy.CONCLUSIONS: High WBC and prolonged PT could predict severe bleeding in high-risk APL patients, while high WBC/D-dimer and low D-dimer/FIB could be independent predictors for thrombosis. For high-risk APL, WBC/D-dimer and D-dimer/FIB are also beneficial in the diagnosis of DIC. WBC/D-dimer might help early identification of thrombosis at the time of admission or during the first week of induction therapy.
peripheral vascular disease,hematology